SPARC与高血压的关联及其在内皮依赖放松中的功能
Xinwei Li1, Wen Zhao1, Xinxin Li1
1Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, 100029, China.
Atherosclerosis
|December 4, 2023
概括
分泌的蛋白酸性和丰富的氨酸 (SPARC) 在高血压中升高,并通过增加氧化应激和减少ACE2损害内皮功能. 恢复ACE2活动可以逆转SPARC.
科学领域:
- 心血管生物学 心血管生物学
- 内皮功能研究研究 内皮功能研究
- 代谢疾病机制 代谢疾病机制
背景情况:
- 分泌的蛋白酸性和丰富的氨酸 (SPARC) 与代谢疾病有关,但其在高血压和内皮功能中的作用尚未得到充分研究.
- 高血压是心血管疾病的主要危险因素,通常与内皮功能障碍有关.
研究的目的:
- 研究SPARC水平与高血压之间的关联.
- 阐明SPARC对内皮依赖放松 (EDR) 和其潜在机制的影响.
主要方法:
- 在110名高血压和正常血压的参与者中测量了血清SPARC度.
- 在SPARC治疗后,对内皮依赖放松 (EDR) 进行了ex vivo和in vivo评估.
- 与内皮功能相关的蛋白质表达,包括ACE2,通过Westernblotting进行分析.
主要成果:
- 血清SPARC水平升高与较高的缩和放缩血压有显著的相关性.
- 在SPARC治疗中,EDR受损,内皮细胞中反应性氧物种 (ROS) 生产增加.
- SPARC降低了血管激素转化酶2 (ACE2) 的表达;ACE2的过度表达减轻了SPARC的有害影响.
结论:
- 这项研究表明,SPARC升高与高血压之间存在显著的相关性.
- 通过减少ACE2表达和增加氧化应激,SPARC对内皮功能产生不利影响.
- 这些发现为与高血压相关的内皮功能障碍和潜在的治疗点提供了新的见解.
更多相关视频
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
748
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748
Neural Regulation of Blood Pressure
2.8K
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
2.8K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
654
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
654
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436


